vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and WESBANCO INC (WSBC). Click either name above to swap in a different company.
WESBANCO INC is the larger business by last-quarter revenue ($257.2M vs $139.2M, roughly 1.8× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 34.5%, a 1.0% gap on every dollar of revenue. Over the past eight quarters, WESBANCO INC's revenue compounded faster (31.9% CAGR vs 30.4%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
WesBanco, Inc., is a bank holding company headquartered in Wheeling, West Virginia, United States. It has over 200 branches in West Virginia, Ohio, Western Pennsylvania, Kentucky, Maryland, and Southern Indiana.
ADMA vs WSBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $257.2M |
| Net Profit | $49.4M | $88.6M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | — |
| Net Margin | 35.5% | 34.5% |
| Revenue YoY | 18.4% | — |
| Net Profit YoY | -55.9% | 54.4% |
| EPS (diluted) | $0.20 | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $257.2M | ||
| Q4 25 | $139.2M | $265.6M | ||
| Q3 25 | $134.2M | $261.6M | ||
| Q2 25 | $122.0M | $260.7M | ||
| Q1 25 | $114.8M | $193.2M | ||
| Q4 24 | $117.5M | $162.9M | ||
| Q3 24 | $119.8M | $150.8M | ||
| Q2 24 | $107.2M | $147.9M |
| Q1 26 | — | $88.6M | ||
| Q4 25 | $49.4M | $91.1M | ||
| Q3 25 | $36.4M | $83.6M | ||
| Q2 25 | $34.2M | $57.4M | ||
| Q1 25 | $26.9M | $-9.0M | ||
| Q4 24 | $111.9M | $49.6M | ||
| Q3 24 | $35.9M | $37.3M | ||
| Q2 24 | $32.1M | $28.9M |
| Q1 26 | — | — | ||
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 45.1% | 43.2% | ||
| Q3 25 | 38.0% | 39.5% | ||
| Q2 25 | 35.1% | 27.2% | ||
| Q1 25 | 30.4% | -5.0% | ||
| Q4 24 | 32.6% | 38.0% | ||
| Q3 24 | 33.1% | 29.7% | ||
| Q2 24 | 36.6% | 23.7% |
| Q1 26 | — | 34.5% | ||
| Q4 25 | 35.5% | 34.3% | ||
| Q3 25 | 27.1% | 31.9% | ||
| Q2 25 | 28.1% | 22.0% | ||
| Q1 25 | 23.4% | -4.7% | ||
| Q4 24 | 95.2% | 30.5% | ||
| Q3 24 | 30.0% | 24.7% | ||
| Q2 24 | 29.9% | 19.5% |
| Q1 26 | — | $0.88 | ||
| Q4 25 | $0.20 | $0.97 | ||
| Q3 25 | $0.15 | $0.84 | ||
| Q2 25 | $0.14 | $0.57 | ||
| Q1 25 | $0.11 | $-0.15 | ||
| Q4 24 | $0.45 | $0.72 | ||
| Q3 24 | $0.15 | $0.54 | ||
| Q2 24 | $0.13 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | — |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $4.1B |
| Total Assets | $624.2M | $27.5B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $87.6M | $956.1M | ||
| Q3 25 | $61.4M | $1.0B | ||
| Q2 25 | $90.3M | $1.2B | ||
| Q1 25 | $71.6M | $1.1B | ||
| Q4 24 | $103.1M | $568.1M | ||
| Q3 24 | $86.7M | $620.9M | ||
| Q2 24 | $88.2M | $486.8M |
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $4.1B | ||
| Q4 25 | $477.3M | $4.0B | ||
| Q3 25 | $431.2M | $4.1B | ||
| Q2 25 | $398.3M | $3.8B | ||
| Q1 25 | $373.4M | $3.8B | ||
| Q4 24 | $349.0M | $2.8B | ||
| Q3 24 | $231.9M | $2.8B | ||
| Q2 24 | $188.3M | $2.5B |
| Q1 26 | — | $27.5B | ||
| Q4 25 | $624.2M | $27.7B | ||
| Q3 25 | $568.7M | $27.5B | ||
| Q2 25 | $558.4M | $27.6B | ||
| Q1 25 | $510.6M | $27.4B | ||
| Q4 24 | $488.7M | $18.7B | ||
| Q3 24 | $390.6M | $18.5B | ||
| Q2 24 | $376.4M | $18.1B |
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | — |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | $290.4M | ||
| Q3 25 | $13.3M | $116.9M | ||
| Q2 25 | $21.1M | $105.0M | ||
| Q1 25 | $-19.7M | $-26.4M | ||
| Q4 24 | $50.2M | $211.0M | ||
| Q3 24 | $25.0M | $60.7M | ||
| Q2 24 | $45.6M | $18.2M |
| Q1 26 | — | — | ||
| Q4 25 | $34.6M | $280.0M | ||
| Q3 25 | $-1.1M | $114.9M | ||
| Q2 25 | $18.7M | $98.3M | ||
| Q1 25 | $-24.4M | $-30.7M | ||
| Q4 24 | $47.5M | $200.7M | ||
| Q3 24 | $24.0M | $56.9M | ||
| Q2 24 | $43.6M | $17.3M |
| Q1 26 | — | — | ||
| Q4 25 | 24.8% | 105.4% | ||
| Q3 25 | -0.8% | 43.9% | ||
| Q2 25 | 15.3% | 37.7% | ||
| Q1 25 | -21.2% | -15.9% | ||
| Q4 24 | 40.4% | 123.2% | ||
| Q3 24 | 20.0% | 37.7% | ||
| Q2 24 | 40.7% | 11.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | 3.9% | ||
| Q3 25 | 10.7% | 0.8% | ||
| Q2 25 | 2.0% | 2.6% | ||
| Q1 25 | 4.1% | 2.2% | ||
| Q4 24 | 2.3% | 6.3% | ||
| Q3 24 | 0.9% | 2.5% | ||
| Q2 24 | 1.9% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.72× | 3.19× | ||
| Q3 25 | 0.36× | 1.40× | ||
| Q2 25 | 0.62× | 1.83× | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | 4.25× | ||
| Q3 24 | 0.70× | 1.63× | ||
| Q2 24 | 1.42× | 0.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
WSBC
| Net Interest Income | $215.4M | 84% |
| Noninterest Income | $41.8M | 16% |
